Narcolepsy Treatments

Find Narcolepsy Treatments

Generic Name

methYLphenidate

Brand Names

Concerta, Cotempla, Daytrana, Jornay, Metadate, Methylin, methYLphenidate Transdermal, QuilliChew, Quillivant, Relexxii, Ritalin

FDA approval date: December 31, 1955

Classification: Central Nervous System Stimulant

Form: Patch, Tablet, Suspension, Capsule, Solution

What is Concerta (methYLphenidate)?

CONCERTA is indicated for the treatment of attention deficit hyperactivity disorder in patients aged 6 to 65 years old. Limitations of Use The use of CONCERTA is not recommended in pediatric patients younger than 6 years of age because they had higher plasma exposure and a higher incidence of adverse reactions than patients 6 years and older at the same dosage [see Warnings and Precautions.

Approved To Treat

Top Global Experts

View All

Save this treatment for later

Not sure about your diagnosis?

Check Your Symptoms

Tired of the same old research?

Check Latest Advances

Related Clinical Trials

Tirzepatide s Dopaminergic Effects in Alcohol Use Disorders (AUD), a Phase 1b Study

Enrollment Status: Recruiting

Publish Date: June 17, 2026

Intervention Type: Drug

Study Phase: Phase 1

Background: Glucagon-like peptide 1 (GLP-1) agonist drugs are used to treat diabetes and aid weight loss. They may also help reduce cravings for drugs and alcohol. Researchers want to know if a GLP-1 drug (tirzepatide) can lessen the urge to drink in people with alcohol use disorder (AUD).

Evaluation of the Relationship Between Medication, Eye Movements, and Autonomic Nervous System Functions in Children and Adolescents With ADHD

Enrollment Status: Recruiting

Publish Date: June 09, 2026

Intervention Type: Drug

Summary: An increasing number of children are being diagnosed with ADHD, and the demand for ADHD medication has been rising. Although ADHD medication is often effective, this is unfortunately not the case for all children and adolescents with ADHD; furthermore, the majority of those who use the medication experience side effects of some kind. There are currently no known factors that are clearly linked to ...

Orexin's Role in The Neurobiology of Substance Use Disorder

Enrollment Status: Recruiting

Publish Date: May 28, 2026

Intervention Type: Drug

Study Phase: Not Applicable

Objectives: The objective is to determine the acute and chronic impact of the orexin antagonist, suvorexant, on neurobiological and behavioral factors linked with substance use disorders. Whether such effects are mediated by baseline characteristics will be tested. Given suvorexant is an FDA approved treatment for insomnia, sleep will be evaluated as well in the nicotine dependent arm. Endpoints: In nicotine-...

View All Clinical Trials